Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
184 hedge funds and large institutions have $2.02B invested in Global Blood Therapeutics, Inc. in 2018 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 73 increasing their positions, 58 reducing their positions, and 37 closing their positions.
198% more call options, than puts
Call options by funds: $75M | Put options by funds: $25.2M
26% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 58
6% less funds holding
Funds holding: 196 → 184 (-12)
14% less capital invested
Capital invested by funds: $2.35B → $2.02B (-$325M)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
32% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$60.1M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$58.4M |
| 3 |
PC
PointState Capital
New York
|
+$24.3M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$20M |
| 5 |
PA
Perceptive Advisors
New York
|
+$14.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$39.3M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$34.8M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$19.7M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$18.3M |
| 5 |
Millennium Management
New York
|
-$10.5M |
GBT Hedge Fund Activity: Q3 2018 in Review
184 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q3 2018, worth a combined $2.02B — down 14% from $2.35B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of GBT and 25 opened new positions — a net loss of 12 holders — while 58 trimmed existing stakes and 73 added.
The largest buyer was Fidelity Investments, adding an estimated $60.1M. The largest seller was Janus Henderson Group, cutting an estimated $39.3M.
- 184 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q3 2018, down from 196 in Q2 2018.
- Funds reported $2.02B of Global Blood Therapeutics, Inc. stock for Q3 2018, down 14% quarter-over-quarter.
- 25 funds opened new Global Blood Therapeutics, Inc. positions in Q3 2018 and 37 closed out, a net change of -12 holders.
- The largest Global Blood Therapeutics, Inc. buyer in Q3 2018 was Fidelity Investments, an estimated $60.1M added.
- The largest Global Blood Therapeutics, Inc. seller in Q3 2018 was Janus Henderson Group, an estimated $39.3M sold.
Based on aggregated 13F filings for Q3 2018.